Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients ; volume:6 ; number:1 ; year:2021 ; pages:38-47
Inflammatory intestinal diseases ; 6, Heft 1 (2021), 38-47
- Creator
-
Reinhold, Ilana
Blümel, Sena
Schreiner, Jens
Boyman, Onur
Bögeholz, Jan
Cheetham, Marcus
Rogler, Gerhard
Biedermann, Luc
Scharl, Michael
- DOI
-
10.1159/000511296
- URN
-
urn:nbn:de:101:1-2021030323204411355203
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Reinhold, Ilana
- Blümel, Sena
- Schreiner, Jens
- Boyman, Onur
- Bögeholz, Jan
- Cheetham, Marcus
- Rogler, Gerhard
- Biedermann, Luc
- Scharl, Michael
Other Objects (12)
Monitoring of anti-TNF biological treatments
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Stopping Anti-TNF in CD Remitters: Cons
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients
A review of ocular adverse events of biological anti-TNF drugs
Monitoring of anti-TNF biological treatments
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Stopping Anti-TNF in CD Remitters: Cons
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients
A review of ocular adverse events of biological anti-TNF drugs
Monitoring of anti-TNF biological treatments
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Stopping Anti-TNF in CD Remitters: Cons
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
Anti-TNF Exposure during Pregnancy in Crohn’s Disease Patients